01.12.2017  Review  Ausgabe 1/2017 Open Access
Hepatitis delta: virological and clinical aspects
 Zeitschrift:
 Virology Journal > Ausgabe 1/2017
Background
Classification
Viral structure
Delta antigen
HDV RNA
Viral replication
Genotypes and epidemiology
Clinical aspects
Diagnosis
Treatment
Drug/Dose

N

Duration

Followup

VRET

SVR

Study


IFN α2a 9MU/m 3×/wk

14

48 wks

6 months

71%

43%

Farci, 1994 [
145]

IFN α2a 3MU/m 3×/wk

14

48 wks

6 months

36%

14%


Placebo

14

48 wks

6 months

0%

8%


IFN α2b 18MU 3×/wk. +

16

6 months

18 months

31%

–

Madejon, 1994 [
146]

9MU 3×/wk. +

1 month


6MU 3×/wk. +

1 month


3MU 3×/wk

4 months


IFN α2a 3MU/day +

16

3 months

18 months

25%

–


1.5MU

9 months


Ribavirin 15 mg/kg/day

9

4 months

12 months

11%

11%

Garripoli, 1994 [
147]

Famciclovir

15

6 months

6 months

6.60%

13.30%

Yurdaydin, 2002 [
148]

Lamivudine 100 mg/day + Placebo

11

52 + 52 wks

16 wks

9.0%

0%

Niro, 2005 [
121]

Lamivudine 100 mg/day

20

104 wks

16 wks

10%

10%


INF α 2a 9MU 3×/wk.

10

24 months

6 months

50%

20%

Günsar, 2005 [
125]

INF α 2a 9MU 3×/wk. + Ribavirin 1–1,2 g/day

21

24 months

6 months

52%

23%


PegINF α 2b 1.5 μg/kg/wk

14

12 months

16 months

57%

43%

Castelnau, 2006 [
149]

PegINF α 2b 1.5 μg/kg/wk

12

12 months

12 months

–

17%

Erhardt, 2006 [
122]

PegIFN α 2b 1.5 μg/kg/wk.

16

18 months

6 months

19%

25%

Niro, 2006 [
150]

PegIFN α 2b 1.5 μg/kg/wk. + Ribavirin 800 mg/day +

22

12 months

6 months

9%

18%


PegIFN α 2b 1.5 μg/kg/wk.

6 months


INF α 2b 10MU 3×/wk

12

12 months

24 months

42%

17%

Canbakan, 2006 [
151]

INF α 2b 10MU 3×/wk. + Lamivudine

14

12 months

24 months

64%

28%


IFN α 2a 9MU 3×/wk

8

12 months

6 months

50%

50%

Yurdaydin, 2008 [
152]

Lamivudine +

14

2 months

6 months

50%

36%


IFN α 2a 9MU 3×/wk. + Lamivudine

10 months


Lamivudine

17

12 months

6 months

12%

12%


PegINF α 2b 1.5 μg/kg/wk

49

13 months

26 months

33%

25%

Gheorge, 2011 [
128]

PegINF α 2b 1.5 μg/kg/wk

11

24 months

6 months

56%

–

Örmeci, 2011 [
153]

7

12 months

6 months

57%

–


PegIFN α 2b 180 μg/wk. + Adefovir 10 mg/day

31

12 months

6 months

23%

26%

Wedemeyer, 2011 [
154]

PegIFN α 2b 180 μg/wk.

29

12 months

6 months

24%

31%


Adefovir 10 mg

30

12 months

6 months

0%

0%


Entecavir 1 g/day

13

48 wks

6 months

23%

–

Kabaçam, 2012 [
124]

PegIFN α 2a 180 μg/wk. ou 2b 1.5 μg/kg/wk

32

24 months

6 months

50%

47%

Karaca, 2013 [
155]

PegIFN α 2b 180 μg/wk. + Entecavir

22
^{a}

12 months

6 months

95%

95%

Borzacov, 2016 [
135]
